VBI Vaccines Inc VBIV

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

NDAQ:VBIV - Post by User

VBI Vaccines Inc

Bullboard Posts

Post by BerkshireCapGrpon Jun 18, 2019 8:16am

93 Views

Post# 29834818

VBIV .71~$2++ PRICE TARGET AND BMO $5 PT! SUPER CHEAP NASDAQ

VBIV .71 HUGE ROOM TO BOUNCE HERE AFTER DROP FROM $2.30 YESTERDAY. EASY MONEY SHORT TERM TRADERS!

NASDAQ BIOTECH STOCK SUPER CHEAP HERE AND STARTING TO RECOVER

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle